Integrated BioPharma's MDC subsidiary names Michael Richtmyer Head of Operations

INTEGRATED BIOPHARMA INC

Michael G. Richtmyer appointed Head of Operations at Manhattan Drug Company, effective August 3, 2026.
Richtmyer brings 35+ years in pharma/nutraceutical ops; was President of Tishcon Corp., overseeing 2 contract manufacturing sites.
He previously worked at Integrated BioPharma from 1991 to 1999 and returns with expanded leadership experience.
Will lead manufacturing, supply chain, quality systems, and scalable growth across MDC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.